BERGEN BRUNSWIG'S MIGRAINE To Bergen Brunswig, it seemed a smart move: Buy a drugmaker to gain a captive source of lucrative products. But when the $9.9 billion drug wholesaler proposed on Nov. 12 to merge with ailing Ivax, the U.S.'s biggest generic drugmaker, Bergen's shares fell 12.6%, to 27 5/8, though they bounced back a bit the next day. Reasons for doubt: Ivax lost $179 million on sharply lower revenues of $223 million in the third quarter. Analysts also wonder if Bergen can retain Ivax competitors as customers. EDITED BY THANE PETERSON RELATED ITEMS CHART: Bergen Brunswig's Stock Price

Updated June 14, 1997 by bwwebmaster
Copyright 1996, by The McGraw-Hill Companies Inc. All rights reserved.
Terms of Use